Phase II trial of concomitant low dose temozolomide with external beam radiation (EBRT) followed by 12 months of temozolomide and irinotecan for newly diagnosed glioblastoma (GBM): Preliminary results of RTOG 04-20. Conference

cited authors

  • Lieberman, FS; Tsien, C; Berkey, B; Curran, W; Werner-Wasik, M; Smith, R; Grossheim, L; Hug, E; Mehta, M

fiu authors

publication date

  • June 20, 2006

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Location

  • Atlanta, GA

Conference

  • 42nd Annual Meeting of the American-Society-of-Clinical-Oncology

start page

  • 60S

end page

  • 60S

volume

  • 24

issue

  • 18